BioTime Creates Asian Subsidiary
In collaboration with a Hong Kong company, the U.S. biotech company BioTime announces the formation of a new subsidiary, to be headquartered in China.
September 25, 2009
In collaboration with a Hong Kong company, the U.S. biotech company BioTime announces the formation of a new subsidiary, to be headquartered in China.
Researchers at Johns Hopkins University are developing new therapies based upon methods of stimulating each person’s own naturally occurring endogenous adult stem cells.
A race horse who was scheduled for retirement is instead returning to his lucrative racing career after being successfully treated with autologous adult stem cell therapy.
The XCell-Center in Germany reports positive clinical results from 45 cerebral palsy patients who were treated with autologous adult stem cells derived from bone marrow, in whom 67% improved as a result of the treatment.
Researchers at the University of Pittsburgh have received two separate NIH grants for the investigation of stem cell growth and differentiation.
In response to the pathetic lack of public awareness about adult stem cells that can be banked from umbilical cord blood, the Cord Blood Registry launches an online education program.